Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuharu Tamaki

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Nature Reviews. Endocrinology|November 24, 2021
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLDNobuharu Tamaki, Veeral Ajmera, Rohit Loomba
Rinsho Byori. the Japanese Journal of Clinical Pathology|January 7, 2016
[Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi
Annals of Laboratory Medicine|August 25, 2020
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver DiseasesNobuharu Tamaki, Masayuki Kurosaki, Rohit Loomba, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver diseaseNobuharu Tamaki, Masayuki Kurosaki, Daniel Q Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 19, 2021
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver DiseaseNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Journal of Medical Ultrasonics (2001)|June 24, 2021
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver diseaseNobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.
Therapeutic Advances in Gastroenterology|May 5, 2022
Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver diseaseVeeral Ajmera, Khang Nguyen, Nobuharu Tamaki, et al.
Journal of Gastroenterology|April 3, 2024
Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver diseaseShun-Ichi Wakabayashi, Nobuharu Tamaki, Takefumi Kimura, et al.
Japanese Journal of Radiology|January 27, 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatmentNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Nature Reviews. Endocrinology|November 24, 2021
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLDNobuharu Tamaki, Veeral Ajmera, Rohit Loomba
Rinsho Byori. the Japanese Journal of Clinical Pathology|January 7, 2016
[Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi
Annals of Laboratory Medicine|August 25, 2020
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver DiseasesNobuharu Tamaki, Masayuki Kurosaki, Rohit Loomba, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver diseaseNobuharu Tamaki, Masayuki Kurosaki, Daniel Q Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 19, 2021
Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver DiseaseNobuharu Tamaki, Mayu Higuchi, Masayuki Kurosaki, et al.
Journal of Medical Ultrasonics (2001)|June 24, 2021
Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver diseaseNobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, et al.
Therapeutic Advances in Gastroenterology|May 5, 2022
Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver diseaseVeeral Ajmera, Khang Nguyen, Nobuharu Tamaki, et al.
Journal of Gastroenterology|April 3, 2024
Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver diseaseShun-Ichi Wakabayashi, Nobuharu Tamaki, Takefumi Kimura, et al.
Japanese Journal of Radiology|January 27, 2026
Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatmentNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2025
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALDNobuharu Tamaki, Takefumi Kimura, Shun-Ichi Wakabayashi, et al.
Pageof 18